ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
18.48
+0.72 (4.05%)
After Hours: 18.20 -0.28 (-1.51%)
Feb 9, 5:18PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.64 - 19.29
52 week 16.64 - 51.99
Open 17.38
Vol / Avg. 2.15M/2.38M
Mkt cap 1.89B
P/E     -
Div/yield     -
EPS -1.47
Shares 100.91M
Beta 3.32
Inst. own 101%
Feb 24, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 10, 2016
ACADIA Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - 8:00AM EST - Add to calendar
Jan 12, 2016
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A session - Webcast
Jan 12, 2016
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -99758.98% -77062.50%
Operating margin -99994.88% -77691.66%
EBITD margin - -77520.00%
Return on average assets -59.92% -35.94%
Return on average equity -64.60% -37.62%
Employees 151 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Chief Financial Officer, Director
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 49
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 56
Bio & Compensation  - Reuters